糖尿病性腎臓病の診かた、考えかた

出版社： 中外医学社
著者：
発行日： 2018-06-20
分野： 臨床医学：内科  >  腎臓
ISBN： 9784498224360
電子書籍版： 2018-06-20 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,620 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,620 円(税込)

購入する

商品紹介

エキスパートの洞察力が身につく最新のバイブル。従来の腎症との違いを理解し、多様化する臨床病態を見抜く。

目次

  • Ch. I 臨床疫学
    　■ 超高齢社会により糖尿病性腎症・糖尿病性腎臓病はどのように変化したか？
    　■ 糖尿病例における正常アルブミン尿かつ腎機能低下例：糖尿病性腎症？
    　■ 2型糖尿病にみられる糖尿病性腎症の早期病変とは？
    　■ 高齢者の糖尿病性腎症の臨床的な特徴は？
    　■ 糖尿病性腎症と腎硬化症
    　■ 現在社会を背景とした糖尿病性腎症レジストリー
    　■ 糖尿病性腎症病期分類2014
    　■ 2型糖尿病例では急性腎障害が起こりやすい
    　■ 糖尿病性腎症とアジア諸国を中心とした国際共同研究の展開
    　■ 糖尿病性腎症は寛解が見込まれるか？
    　■ アルブミン尿・蛋白尿が改善すると予後の改善も見込まれる？
    　■ 糖尿病性腎症とチーム医療

    Ch. II 病理・臨床像
    　■ 腎生検の適応
    　■ 病理所見の定義とその鑑別
    　■ 糖尿病性腎症と腎硬化症
    　■ 病理所見の臨床的意義

    Ch. III 診断・バイオマーカー
    　■ 臨床診断
    　■ 病理診断
    　■ 臨床的バイオマーカー
    　■ 基礎的バイオマーカー

    Ch. IV 治療 1：生活習慣に関わる治療・指導
    1 生活指導・運動療法
    　■ 生活指導の実際
    　■ 運動療法
    2 食事療法 ［鈴木芳樹］
    　■ CKDおよび腎症の食事療法基準
    　■ エネルギー
    　■ 蛋白質
    　■ ナトリウム（食塩）
    　■ カリウム
    　■ リン
    　■ CKDおよび腎症におけるLPDに関するエビデンス
    　■ 体重の取り扱い方
    　■ 注目されている問題および今後の食事療法の展望

    Ch. V 治療 2：血圧管理［柏原直樹］
    　■ 治療の基本方針
    　■ 糖尿病性腎症の基盤病態
    　■ 糖尿病性腎症における血圧管理：130/80mmHg未満の厳格な降圧が必要
    　■ 糖尿病性腎症の第一選択薬：RA系阻害薬
    　■ 降圧薬併用療法

    Ch. VI 治療 3：血糖管理と新しい治療法の開発
    1 G1～G3aの血糖コントロール
    　■ 糖尿病性腎症の病期分類
    　■ 血糖コントロールと腎症の進展抑制
    　■ 血糖コントロール上の留意点
    　■ G3aにおける薬物療法上の留意点
    2 G3b以降の血糖コントロール
    　■ 経口血糖降下薬
    　■ インスリン製剤
    　■ GLP-1受容体作動薬
    Column 1　糖尿病性腎症の透析管理
    3 糖尿病治療薬の選択
    　■ 糖尿病治療薬の選択にあたって
    　■ 腎保護作用が期待される糖尿病治療薬
    4 集約的治療
    　■ 糖尿病性腎症に対する集約的治療
    　■ 早期腎症を有する2型糖尿病に対する集約的治療の効果
    　■ 顕性腎症患者に対する集約的治療の効果
    　■ 本邦における糖尿病性腎症の進展抑制のための集約的治療
    Column 2 チーム医療の実践スキル
    5 期待される今後の治療薬
    　■ 糖尿病性腎症の成因と治療薬
    　■ 新たな糖尿病治療薬の開発
    　■ エンドセリン受容体拮抗薬

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Ch. I 臨床疫学

P.25 掲載の参考文献
1) Anguiano Gomez L, Lei Y, Kumar Devarapu S, et al. The diabetes pandemic suggests unmet needs for 'CKD with diabetes' in addition to 'diabetic nephropathy' -implications for pre-clinical research and drug testing. Nephrol Dial Transplant. 2017 Jul 31. doi : 10.1093/ndt/gfx219. [Epub ahead of print]
 
2) Katayama S, Moriya T, Tanaka S, et al, Low transition rate from normoand low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals : the Japan Diabetes Complications Study (JDCS). Diabetologia. 2011 ; 54 : 1025-31.
 
3) Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. 2016 ; 316 : 602-10.
PubMed
4) Shimizu M, Furuichi K, Yokoyama H, et al. Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency. Clin Exp Nephrol. 2014 ; 18 : 305-12.
PubMed
5) Klessens CQ, Woutman TD, Veraar KA, et al. An autopsy study suggests that diabetic nephropathy is underdiagnosed. Kidney Int. 2016 ; 90 : 149-56.
PubMed
6) Furuichi K, Yuzawa Y, Shimizu M, et al. Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes. Nephrol Transplant Dia. 2017 ; 33 : 138-48.
 
7) Tanaka Y, Atsumi Y, Matsuoka K, et al. Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care. 1998 ; 21 : 116-20.
PubMed
8) Furuichi K, Shimizu M, Yuzawa Y, et al. Clinicopathological analysis of biopsy-proven diabetic nephropathy based on the Japanese classification of diabetic nephropathy. Clin Exp Nephrol. 2017 Oct 27. doi : 10.1007/s10157-017-1485-7. [Epub ahead of print]
 
9) Shimizu M, Furuichi K, Toyama T, et al. Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy. Diabetes Care. 2013 ; 36 : 3655-62.
PubMed
10) Shimizu M, Furuichi K, Toyama T, et al. Decline in estimated glomerular filtration rate is associated with risk of end-stage renal disease in type 2 diabetes with macroalbuminuria : an observational study from JDNCS. Clin Exp Nephrol. 2018 ; 22 : 377-87.
PubMed
11) 羽田勝計, 宇都宮一典, 古家大祐, 他. 委員会報告 糖尿病性腎症病期分類2014の策定 (糖尿病性腎症病期分類改訂) について. 日腎会誌. 2014 ; 56 : 547-52.
 
12) Wada T, Haneda M, Furuichi K, et al. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clin Exp Nephrol. 2014 ; 18 : 613-20.
PubMed
13) Toyama T, Furuichi K, Ninomiya T, et al. The impacts of albuminuria and low eGFR on the risk of cardiovascular death, all-cause mortality, and renal events in diabetic patients : meta-analysis. PLoS One. 2013 ; 8 : e71810.
PubMed
14) Thakar CV, Christianson A, Himmelfarb J, et al. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol. 2011 ; 6 : 2567-72.
PubMed
15) Hsu RK, Hsu CY. Proteinuria and reduced glomerular filtration rate as risk factors for acute kidney injury. Curr Opin Nephrol Hypertens. 2011 ; 20 : 211-7.
PubMed
16) Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease : a systematic review. Lancet. 2015 ; 385 : 1975-82.
PubMed
17) Chen PM, Wada T, Chiang CK. Prognostic value of proteinuria and glomerular filtration rate on Taiwanese patients with diabetes mellitus and advanced chronic kidney disease : a single center experience. Clin Exp Nephrol. 2017 ; 21 : 307-15.
PubMed
18) Yokoyama H, Araki S, Honjo J, et al. Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria. Diabetes Care. 2013 ; 36 : 3227-33.
PubMed
19) 腎障害進展予防と腎代替療法への移行CKDステージG3b-5診療ガイドライン 2015. http://reach-j.jp/wp-content/uploads/2015/07/guideline.pdf
 
20) Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016 ; 375 : 323-34.
PubMed
21) Wada T, Muso E, Maruyama S, et al. Rationale and study design of a clinical trial to assess the effects of LDL apheresis on proteinuria in diabetic patients with severe proteinuria and dyslipidemia. Clin Exp Nephrol. 2017 Oct 27. doi : 10.1007/s10157-017-1488-4. [Epub ahead of print]
 
22) Yamagata K, Makino H, Iseki K, et al. Effect of Behavior Modification on Outcome in Early- to Moderate-Stage Chronic Kidney Disease : A Cluster-Randomized Trial. PLoS One. 2016 ; 11 : e0151422.
PubMed
23) 日本腎臓学会. https://www.jsn.or.jp/topics/notice/_3410.php
 

Ch. II 病理・臨床像

P.61 掲載の参考文献
1) Katayama S, Moriya T, Tanaka S, et al. Low transition rate from normoand low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals : the Japan Diabetes Complications Study (JDCS). Diabetologia. 2011 ; 54 : 1025-31.
 
2) Sharma SG, Bomback AS, Radhakrishnan J, et al. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol. 2013 ; 8 : 1718-24.
PubMed
3) Shimizu M, Furuichi K, Toyama T, et al. Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy. Diabetes Care. 2013 ; 36 : 3655-62.
PubMed
4) Gellman DD, Pirani CL, Soothill JF, et al. Diabetic nephropathy : a clinical and pathologic study based on renal biopsies. Medicine (Baltimore). 1959 ; 38 : 321-67.
PubMed
5) Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010 ; 21 : 556-63.
PubMed
6) 和田隆志, 湯澤由紀夫, 監修. 糖尿病性腎症と高血圧性腎硬化症の病理診断への手引き. 東京 : 東京医学社 ; 2015.
 
7) Working Group of the International Ig ANN, the Renal Pathology Society, Roberts IS, et al. The Oxford classification of IgA nephropathy : pathology definitions, correlations, and reproducibility. Kidney Int. 2009 ; 76 : 546-56.
 
8) Najafian B, Alpers CE, Fogo AB. Pathology of human diabetic nephropathy. Contrib Nephrol. 2011 ; 170 : 36-47.
PubMed
9) Nyumura I, Honda K, Tanabe K, et al. Early histologic lesions and risk factors for recurrence of diabetic kidney disease after kidney transplantation. Transplantation. 2012 ; 94 : 612-9.
PubMed
10) Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol. 2007 ; 27 : 195-207.
PubMed
11) Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol. 1936 ; 12 : 83-98. 7.
 
12) Wada T, Shimizu M, Yokoyama H, et al. Nodular lesions and mesangiolysis in diabetic nephropathy. Clin Exp Nephrol. 2013 ; 17 : 3-9.
PubMed
13) Mise K, Ueno T, Hoshino J, et al. Nodular lesions in diabetic nephropathy : collagen staining and renal prognosis. Diabetes Res Clin Pract. 2017 ; 127 : 187-97.
PubMed
14) 北村博司. 腎生検病理アトラス-糖尿病性腎症. 第2版. 東京 : 東京医学社 ; 2010.
 
15) Hong D, Zheng T, Jia-qing S, et al. Nodular glomerular lesion : a later stage of diabetic nephropathy? Diabetes Res Clin Pract. 2007 ; 78 : 189-95.
PubMed
16) Furuichi K, Yuzawa Y, Shimizu M, et al. Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes. Nephrol Dial Transplant. 2017. doi : 10.1093/ndt/gfw417. [Epub ahead of print]
 
17) Raparia K, Usman I, Kanwar YS. Renal morphologic lesions reminiscent of diabetic nephropathy. Arch Pathol Lab Med. 2013 ; 137 : 351-9.
PubMed
18) Nasr SH, D'Agati VD. Nodular glomerulosclerosis in the nondiabetic smoker. J Am Soc Nephrol. 2007 ; 18 : 2032-6.
 
19) Stout LC, Kumar S, Whorton EB. Focal mesangiolysis and the pathogenesis of the Kimmelstiel-Wilson nodule. Hum Pathol. 1993 ; 24 : 77-89.
PubMed
20) Camici M. Renal glomerular permselectivity and vascular endothelium. Biomed Pharmacother. 2005 ; 59 : 30-7.
PubMed
21) Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008 ; 88 : 451-87.
PubMed
22) Haraldsson B, Nystrom J. The glomerular endothelium : new insights on function and structure. Curr Opin Nephrol Hypertens. 2012 ; 21 : 258-63.
PubMed
23) 山中宣昭. 【糖尿病のすべて】糖尿病性糸球体硬化症とその進展. 腎と透析. 2001 ; 51 : 209-16.
 
24) 北村博司. 糖尿病性腎症の組織分類. In : 日本腎臓学会・腎病理診断標準化委員会, 編. 腎生検病理診断標準化への指針. 東京 : 東京医学社 ; 2005.
 
25) Saito Y, Kida H, Takeda S, et al. Mesangiolysis in diabetic glomeruli : its role in the formation of nodular lesions. Kidney Int. 1988 ; 34 : 389-96.
PubMed
26) Jennete JC, Olson JL, Schwartz MM, et al. Heptinstall's Pathology of the Kidney. 6th ed. Lippincott Williams & Wilkins ; 2007.
 
27) Olson JL, de Urdaneta AG, Heptinstall RH. Glomerular hyalinosis and its relation to hyperfiltration. Lab Invest. 1985 ; 52 : 387-98.
PubMed
28) Stout LC, Kumar S, Whorton EB. Insudative lesions-their pathogenesis and association with glomerular obsolescence in diabetes : a dynamic hypothesis based on single views of advancing human diabetic nephropathy. Hum Pathol. 1994 ; 25 : 1213-27.
PubMed
29) Mise K, Hoshino J, Ubara Y, et al. Renal prognosis a long time after renal biopsy on patients with diabetic nephropathy. Nephrol Dial Transplant. 2014 ; 29 : 109-18.
PubMed
30) Bloodworth JM Jr. A re-evaluation of diabetic glomerulosclerosis 50 years after the discovery of insulin. Hum Pathol. 1978 ; 9 : 439-53.
PubMed
31) Nelson RG, Bennett PH, Beck GJ, et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med. 1996 ; 335 : 1636-42.
 
32) Hiragushi K, Sugimoto H, Shikata K, et al. Nitric oxide system is involved in glomerular hyperfiltration in Japanese normo-and micro-albuminuric patients with type 2 diabetes. Diabetes Res Clin Pract. 2001 ; 53 : 149-59.
PubMed
33) Osterby R, Bangstad HJ, Nyberg G, et al. On glomerular structural alterations in type-1 diabetes. Companions of early diabetic glomerulopathy. Virchows Arch. 2001 ; 438 : 129-35.
PubMed
34) Osterby R, Nyberg G. New vessel formation in the renal corpuscles in advanced diabetic glomerulopathy. J Diabet Complications. 1987 ; 1 : 122-7.
PubMed
35) Nakagawa T, Kosugi T, Haneda M, et al. Abnormal angiogenesis in diabetic nephropathy. Diabetes. 2009 ; 58 : 1471-8.
PubMed
36) McGinn S, Saad S, Poronnik P, et al. High glucose-mediated effects on endothelial cell proliferation occur via p38 MAP kinase. Am J Physiol Endocrinol Metab. 2003 ; 285 : E708-17.
PubMed
37) Marcantoni C, Ma LJ, Federspiel C, et al. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int. 2002 ; 62 : 172-80.
PubMed
38) Marcantoni C, Fogo AB. A perspective on arterionephrosclerosis : from pathology to potential pathogenesis. J Nephrol. 2007 ; 20 : 518-24.
PubMed
39) Kawamura T, Joh K, Okonogi H, et al. A histologic classification of IgA nephropathy for predicting long-term prognosis : emphasis on end-stage renal disease. J Nephrol. 2013 ; 26 : 350-7.
PubMed
40) Howie AJ, Brewer DB. The glomerular tip lesion : a previously undescribed type of segmental glomerular abnormality. J Pathol. 1984 ; 142 : 205-20.
PubMed
41) Najafian B, Mauer M. Predilection of segmental glomerulosclerosis lesions for the glomerulotubular junction area in type 1 diabetic patients : a novel mapping method. PLoS One. 2013 ; 8 : e69253.
PubMed
42) Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report : differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant. 2007 ; 7 : 518-26.
 
43) Sun YM, Su Y, Li J, et al. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun. 2013 ; 433 : 359-61.
 
44) Thomas MC. Advanced glycation end products. Contrib Nephrol. 2011 ; 170 : 66-74.
PubMed
45) Tesch GH, Lim AK. Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. Am J Physiol Renal Physiol. 2011 ; 300 : F301-10.
PubMed
46) Lin M, Tang SC. Toll-like receptors : sensing and reacting to diabetic injury in the kidney. Nephrol Dial Transplant. 2014 ; 29 : 746-54.
PubMed
47) Okada T, Nagao T, Matsumoto H, et al. Histological predictors for renal prognosis in diabetic nephropathy in diabetes mellitus type 2 patients with overt proteinuria. Nephrology (Carlton). 2012 ; 17 : 68-75.
PubMed
48) Shimizu M, Furuichi K, Yokoyama H, et al. Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency. Clin Exp Nephrol. 2014 ; 18 : 305-12.
PubMed
49) Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease : more than an aftermath of glomerular injury? Kidney Int. 1999 ; 56 : 1627-37.
PubMed
50) Bohle A, Wehrmann M, Bogenschutz O, et al. The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract. 1991 ; 187 : 251-9.
PubMed
51) Katz A, Caramori ML, Sisson-Ross S, et al. An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients. Kidney Int. 2002 ; 61 : 2058-66.
PubMed
52) Lewis A, Steadman R, Manley P, et al. Diabetic nephropathy, inflammation, hyaluronan and interstitial fibrosis. Histol Histopathol. 2008 ; 23 : 731-9.
PubMed
53) Kosugi T, Yuzawa Y, Sato W, et al. Midkine is involved in tubulointerstitial inflammation associated with diabetic nephropathy. Lab Invest. 2007 ; 87 : 903-13.
PubMed
54) Wada T, Furuichi K, Sakai N, et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 2000 ; 58 : 1492-9.
PubMed
55) Lipkowitz MS, Freedman BI, Langefeld CD, et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 2013 ; 83 : 114-20.
PubMed
56) 日本透析医学会. 図説 わが国の慢性透析療法の現況 2015年12月31日現在. 2016.
 
57) Shiraishi N, Kitamura K, Kohda Y, et al. Prevalence and risk factor analysis of nephrosclerosis and ischemic nephropathy in the Japanese general population. Clin Exp Nephrol. 2014 ; 18 : 461-8.
PubMed
58) Abe M, Okada K, Maruyama N, et al. Comparison of clinical trajectories before initiation of renal replacement therapy between diabetic nephropathy and nephrosclerosis on the KDIGO Guidelines Heat Map. J Diabetes Res. 2016 ; 2016 : 5374746.
PubMed
59) Krolewski AS. Progressive renal decline : the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2015 ; 38 : 954-62.
PubMed
60) Moriya T, Suzuki Y, Inomata S, et al. Renal histological heterogeneity and functional progress in normoalbuminuric and microalbuminuric Japanese patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2014 ; 2 : e000029.
PubMed
61) Mise K, Hoshino J, Ueno T, et al. Clinical implications of linear immunofluorescent staining for immunoglobulin G in patients with diabetic nephropathy. Diabetes Res Clin Pract. 2014 ; 106 : 522-30.
PubMed
62) Mise K, Hoshino J, Ueno T, et al. Impact of tubulointerstitial lesions on anaemia in patients with biopsy-proven diabetic nephropathy. Diabet Med. 2015 ; 32 : 546-55.
PubMed

Ch. III 診断・バイオマーカー

P.101 掲載の参考文献
1) 糖尿病診断基準に関する調査検討委員会. 糖尿病の分類と診断基準に関する委員会報告 (国際標準化対応版). 糖尿病. 2012 ; 55 : 494.
 
2) 日本臨床内科医会調査研究グループ. 糖尿病性神経障害に関する調査研究第1報 わが国の糖尿病の実態と合併症. 日臨内科医会誌. 2001 ; 16 : 167-95.
 
3) The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 ; 329 : 977-86
 
4) 槇野博史. 糖尿病性腎症-発症・進展機序と治療. 東京 : 診断と治療社 ; 1999. p.192.
 
5) 猪股茂樹, 羽田勝計, 守屋達美, 他. 糖尿病性腎症の新しい早期診断基準. 糖尿病. 2005 ; 48 : 757-9.
 
6) Said SM, Nasr SH. Silent diabetic nephropathy. Kidney Int. 2016 ; 90 : 24-6.
PubMed
7) Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease : challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017. doi : 10.2215/CJN.11491116. [Epub ahead of print]
 
8) Furuichi K, Yuzawa Y, Shimizu M, et al. Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes. Nephrol Dial Transplant. 2017. doi : 10.1093/ndt/gfw 417. [Epub ahead of print]
 
9) Ichihara A, Hayashi M, Kaneshiro Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest. 2004 ; 114 : 1128-35.
 
10) Tuttle KR. Back to the future : glomerular hyperfiltration and the diabetic kidney. Diabetes. 2017 ; 66 : 14-6.
 
11) Kashihara N, Haruna Y, Kondeti VK, et al. Oxidative stress in diabetic nephropathy. Curr Med Chem. 2010 ; 17 : 4256-69.
PubMed
12) 羽田勝計, 宇都宮一典, 古家大祐, 他. 糖尿病性腎症病期分類2014の策定 (糖尿病性腎症病期分類改訂) について. 日腎会誌. 2014 ; 56 : 547-52.
 
13) Zylka A, Gala-Bladzinska A, Rybak K, et al. Role of new biomarkers for the diagnosis of nephropathy associated with diabetes type 2. Folia Med Cracov. 2015 ; 55 : 21-33.
PubMed
14) 稲熊大城, 秋山真一, 湯澤由紀夫. バイオマーカーの進歩. 日腎会誌. 2017 ; 59 : 65-73.
 
15) Inaguma D, Imai E, Takeuchi A, et al ; Chronic Kidney Disease Japan Cohort Study Group. Risk factors for CKD progression in Japanese patients : findings from the Chronic Kidney Disease Japan Cohort (CKD-JAC) study. Clin Exp Nephrol. 2017 ; 21 : 446-56.
 
16) Yoshikawa M, Hishikawa K, Marumo T, et al. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol. 2007 ; 18 : 58-65.
PubMed
17) Hirayama A, Nakashima E, Sugimoto M, et al. Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy. Anal Bioanal Chem. 2012 ; 404 : 3101-9.
PubMed

Ch. IV 治療 ( 1 ) : 生活習慣に関わる治療・指導

P.120 掲載の参考文献
1) Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002 ; 288 : 1775-9.
PubMed
2) Duncan I, Birkmeyer C, Coughlin S, et al. Assessing the value of diabetes education. Diabetes Educ. 2009 ; 35 : 752-60.
PubMed
3) Funnell MM, Brown TL, Childs BP, et al. National standards for diabetes self-management education. Diabetes Care. 2007 ; 30 : 1630-7.
PubMed
4) Heisler M, Resnicow K. Helping patients make and sustain health changes : a brief introduction to motivational interviewing. Clin Diabetes. 2008 ; 26 : 161-5.
 
5) Funnell MM, Anderson RM. Changing healthcare systems and office practice to facilitate patient self-management. Curr Diab Rep. 2003 ; 3 : 127-33.
PubMed
6) Burant CF, ed. Medical management of type 2 diabetes. 7th ed. American Diabetes Association ; 2012.
 
7) 日本糖尿病学会, 編. 糖尿病治療ガイド 2016-2017. 東京 : 文光堂 ; 2016.
 
8) Van Huffel L, Tomson CR, Ruige J, et al. Dietary restriction and exercise for diabetic patients with chronic kidney disease : a systematic review. PLoS One. 2014 ; 9 : e113667.
PubMed
9) Leehey DJ, Moinuddin I, Bast JP, et al. Aerobic exercise in obese diabetic patients with chronic kidney disease : a randomized and controlled pilot study. Cardiovasc Diabetol. 2009 ; 8 : 62.
PubMed
10) Matsuoka K, Nakao T, Atsumi Y, et al. Exercise regimen for patients with diabetic nephropathy. J Diabet Complications. 1991 ; 5 : 98-100.
PubMed
11) Morales E, Valero MA, Leon M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003 ; 41 : 319-27.
PubMed
12) Castaneda C, Layne JE, Munoz-Orians L, et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care. 2002 ; 25 : 2335-41.
PubMed
13) Sigal RJ, Kenny GP, Boule NG, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes : a randomized trial. Ann Intern Med. 2007 ; 147 : 357-69.
 
P.137 掲載の参考文献
1) 日本腎臓学会, 編. 慢性腎臓病に対する食事療法基準2014年版. 東京 : 東京医学社 ; 2014.
 
2) 日本糖尿病学会, 編. 糖尿病治療ガイド 2016-2017. 東京 : 文光堂 ; 2016.
 
3) 厚生労働省. 日本人の食事摂取基準 (2015年版). 2015.
 
4) 日本腎臓学会, 編. エビデンスに基づくCKD診療ガイドライン 2013. 東京 : 東京医学社 ; 2013.
 
5) Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev. 2009 ; (3) : CD001892.
PubMed
6) Aparicio M, Bellizzi V, Chauveau P, et al. Do ketoanalogues still have a role in delaying dialysis initiation in CKD predialysis patients? Semin Dial. 2013 ; 26 : 714-9.
PubMed
7) Ideura T, Shimazui M, Morita H, et al. Protein intake of more than 0.5 g/kg BW/day is not effective in suppressing the progression of chronic renal failure. Contrib Nephrol. 2007 ; 155 : 40-9.
 
8) Rughooputh MS, Zeng R, Yao Y. Protein diet restriction slows chronic kidney disease progression in non-diabetic and in type 1 diabetic patients, but not in type 2 diabetic patients : A meta-analysis of randomized controlled trials using glomerular filtration rate as a surrogate. PLoS One. 2015 ; 10 : e0145505.
 
9) Cianciaruso B, Pota A, Bellizzi V, et al. Effect of a low- versus moderate-protein diet on progression of CKD : follow-up of a randomized controlled trial. Am J Kidney Dis. 2009 ; 54 : 1052-61.
PubMed
10) Pan Y, Guo LL, Jin HM. Low-protein diet for diabetic nephropathy : a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008 ; 88 : 660-6.
PubMed
11) Nezu U, Kamiyama H, Kondo Y, et al. Effect of low-protein diet on kidney function in diabetic nephropathy : meta-analysis of randomised controlled trials. BMJ Open. 2003 ; 3 : e002934.
 
12) Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia : consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014 ; 15 : 95-101.
 
13) 日本サルコペニア・フレイル学会, 編. サルコペニア診療ガイドライン 2017年版. 東京 : ライフサイエンス出版 ; 2017.
 
14) Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008 ; 73 : 391-8.
PubMed
15) Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016 ; 375 : 323-34.
PubMed

Ch. V 治療 ( 2 ) : 血圧管理

P.151 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会. 高血圧治療ガイドライン 2014. 東京 : ライフサイエンス出版 ; 2014.
 
2) エビデンスに基づくCKD診療ガイドライン作成委員会, 日本腎臓学会. エビデンスに基づくCKD診療ガイドライン 2013. 日腎会誌. 2013 ; 55 : 585-860.
 
3) 柏原直樹. 糖尿病患者の腎臓を守ろう. In : 慢性腎臓病CKD : 病態理解に基づいた予防と治療のあり方. 東京 : メディカルレビュー社 ; 2009. p.25-39.
 
4) Satoh M, Kobayashi S, Kuwabara A, et al. In vivo visualization of glomerular microcirculation and hyperfiltration in streptozotocin- induced diabetic rats. Microcirculation. 2010 ; 17 : 103-12.
PubMed
5) Parving HH, Kastrup H, Smidt UM, et al. Impaired autoregulation of glomerular filtration rate in type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia. 1984 ; 27 : 547-52.
PubMed
6) Ichihara A, Kaneshiro Y, Takemitsu T, et al. The (pro) renin receptor and the kidney. Semin Nephrol. 2007 ; 27 : 524-8.
PubMed
7) Satoh M, Fujimoto S, Haruna Y, et al. NAD (P) H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2005 ; 288 : F1144-52.
PubMed
8) Satoh M, Fujimoto S, Arakawa S, et al. Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrol Dial Transplant. 2008 ; 23 : 3806-13.
PubMed
9) Kidokoro K, Satoh M, Channon KM, et al. Maintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy. J Am Soc Nephrol. 2013 ; 24 : 1139-50.
PubMed
10) Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 ; 362 : 1575-85.
PubMed
11) Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose : observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation. 2011 ; 123 : 2799-810, 9 p following 810.
PubMed
12) Andersen S, Brochner-Mortensen J, Parving HH. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care. 2003 ; 26 : 3296-302.
PubMed
13) Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007 ; 30 : 1577-8.
PubMed
14) Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 ; 345 : 861-9.
PubMed
15) Imai E, Chan JC, Ito S, et al : ORIENT study investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy : a multicentre, randomised, placebo-controlled study. Diabetologia. 2011 ; 54 : 2978-86.
 
16) Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004 ; 351 : 1941-51.
PubMed
17) Mauer M, Zinman B, Gardiner R, et al Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009 ; 361 : 40-51.
PubMed
18) Hollenberg NK, Fisher ND. Renal circulation and blockade of therenin-angiotensin system. Is angiotensin-converting enzyme inhibition the lastword? Hypertension. 1995 ; 26 : 602-9.
 
19) Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 ; 358 : 1547-59.
 
20) Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 ; 367 : 2204-13.
 

Ch. VI 治療 ( 3 ) : 血糖管理と新しい治療法の開発

P.160 掲載の参考文献
1) Shikata K, Makino H. Microinflammation in the pathogenesis of diabetic nephropathy. J Diabetes Investig. 2013 ; 4 : 142-9.
PubMed
2) Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes : the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003 ; 63 : 225-32.
PubMed
3) 糖尿病性腎症合同委員会. 糖尿病性腎症病期分類2014の策定 (糖尿病性腎症病期分類改訂) について. 糖尿病. 2014 ; 57 : 529-34.
 
4) American Diabetes Association 10. Microvascular complications and foot care. Diabetes Care. 2017 ; 40 : S88-98.
 
5) Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003 ; 348 : 2285-93.
PubMed
6) Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria : the Steno type 2 randomised study. Lancet. 1999 ; 353 : 617-22.
PubMed
7) The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 ; 329 : 977-86.
 
8) UK Prospectiove Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 ; 352 : 837-53.
 
9) Group AC, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 ; 358 : 2560-72.
 
10) Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995 ; 28 : 103-17.
PubMed
11) The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000 ; 342 : 381-9.
 
12) Group DER, de Boer IH, Sun W, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011 ; 365 : 2366-76.
 
13) Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013 ; 83 : 517-23.
PubMed
14) Coca SG, Ismail-Beigi F, Haq N, et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus : systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med. 2012 ; 172 : 761-9.
PubMed
15) Action to Control Cardiovascular Risk in Diabetes Study G Group, Gerstein, HC, Miller, ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 ; 358 : 2545-59.
 
16) Papademetriou V, Lovato L, Doumas M, et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int. 2015 ; 87 : 649-59.
PubMed
17) Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes : meta-analysis of randomised controlled trials. BMJ. 2011 ; 343 : d4169.
PubMed
18) Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998 ; 116 : 874-86.
PubMed
19) The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol. 1995 ; 113 : 36-51.
PubMed
20) ビグアナイド薬の適正使用に関する委員会. メトホルミンの適正使用に関するRecommendation (2016年5月12日改訂) http://www.jds.or.jp/modules/important/index.php?page=article&storyid=20
 
21) Eppenga WL, Lalmohamed A, Geerts AF, et al. Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment : a population-based cohort study. Diabetes Care. 2014 ; 37 : 2218-24.
PubMed
P.169 掲載の参考文献
1) 一般社団法人日本透析医学会. 図説わが国の慢性透析療法の現況. http://www.jsdt.or.jp/overview_confirm.html
 
2) The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 ; 329 : 977-86.
 
3) UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes (UKPDS33). Lancet. 1998 ; 352 : 837-53.
 
4) Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995 ; 28 : 103-17.
PubMed
5) Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 ; 358 : 2560-72.
PubMed
6) Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycemia on microvascular outcomes in type 2 diabetes. : an analysis of the ACCORD randomized trial. Lancet. 2010 ; 376 : 419-30.
PubMed
7) Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 ; 360 : 129-39.
PubMed
8) Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes : effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007 ; 18 : 896-903.
PubMed
9) Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease : a population-based cohort study. Arch Intern Med. 2011 ; 171 : 1920-27.
PubMed
10) Hill CJ, Maxwell AP, Cardwell CR, et al. Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis : a meta-analysis. Am J Kidney Dis. 2014 ; 63 : 84-94.
PubMed
社団法人日本腎臓学会. CKD診療ガイド 2012. 東京 : 東京医学社 ; 2012.
 
一般社団法人日本腎臓学会. エビデンスに基づくCKD診療ガイドライン 2013. 東京 : 東京医学社 ; 2016.
 
日本糖尿病学会. 糖尿病診療ガイドライン 2016. 東京 : 南江堂 ; 2016.
 
各社添付文書, インタビューフォーム.
 
P.180 掲載の参考文献
1) 政金生人, 谷口正智, 中井滋, 他. わが国の慢性透析療法の現況 (2015年12月31日現在). 透析会誌. 2017 ; 50 : 1-62.
 
2) Wakasugi M, Kazama JJ, Narita I. Mortality trends among Japanese dialysis patients, 1988-2013 : a joinpoint regression analysis. Nephrol Dial Transplant. 2016 ; 31 : 1501-7.
PubMed
3) 前田貞亮. 糖尿病と透析療法. 東京 : 日本メディカルセンター ; 1996.
 
4) 日本透析医学会. 血液透析患者の糖尿病治療ガイド 2012. 透析会誌. 2013 ; 46 : 311-57.
 
5) Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes : effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007 ; 18 : 896-903.
PubMed
6) Fukuoka K, Nakao K, Morimoto H, et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology. 2008 ; 13 : 278-83.
PubMed
7) Inaba M, Maekawa K, Okuno S, et al. Impact of atherosclerosis on the relationship of glycemic control and mortality in diabetic patients on hemodialysis. Clin Nephrol. 2012 ; 78 : 273-80.
PubMed
8) Kalantar-Zadeh K, Kopple JD, Regidor DL, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007 ; 30 : 1049-55.
PubMed
9) Hoshino J, Larkina M, Karaboyas A, et al. Unique hemoglobin A1c level distribution and its relationship with mortality in diabetic hemodialysis patients. Kidney Int. 2017 ; 92 : 497-503.
PubMed
10) Wu MS, Yu CC, Yang CW, et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemo dialysis. Nephrol Dial Transplant. 1997 ; 12 : 2105-10.
 
11) Morioka T, Emoto M, Tabata T. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care. 2001 ; 24 : 909-13.
PubMed
12) Oomichi T, Emoto M, Tabata T, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis : a 7-year observational study. Diabetes Care. 2006 ; 29 : 1496-500.
PubMed
13) Williams ME, Lacson E Jr, Teng M, et al. Hemodialyzed type I and type II diabetic patients in the US : Characteristics, glycemic control, and survival. Kidney Int. 2006 ; 70 : 1503-9.
PubMed
14) Ishimura E, Okuno S, Kono K, et al. Glycemic control and survival of diabetic hemodialysis patients--importance of lower hemoglobin A1C levels. Diabetes Res Clin Pract. 2009 ; 83 : 320-6.
PubMed
15) Matsubara Y, Kimachi M, Fukuma S, et al. Development of a new risk model for predicting cardiovascular events among hemodialysis patients : Population-based hemodialysis patients from the Japan Dialysis Outcome and Practice Patterns Study (J-DOPPS). PLoS One. 2017 ; 12 : e0173468.
PubMed
16) 日本透析医学会統計調査委員会・統計解析小委員会. わが国の慢性透析療法の現況 (2007年12月31日). 透析会誌. 2009 ; 42 : 1-45.
 
17) Yamagata K, Nakai S, Masakane I, et al. Ideal timing and predialysis nephrology care duration for dialysis initiation : from analysis of Japanese dialysis initiation survey. Ther Apher Dial. 2012 ; 16 : 54-62.
PubMed
18) 大友貴史, 雨宮守正, 井岡崇, 他. 糖尿病性腎症と慢性糸球体腎炎による透析導入時の特徴とその移り変わりの検討 : 自治医科大学における血液透析導入の検討 (2). 透析会誌. 2000 ; 33 : 1143-8.
 
19) Banerjee D, Ma JZ, Collins AJ, et al. Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload. Clin J Am Soc Nephrol. 2007 ; 2 : 1186-90.
PubMed
20) 日本透析医学会. 維持血液透析ガイドライン : 血液透析処方. 透析会誌. 2013 ; 46 : 587-632.
 
21) 日本透析医学会. 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌. 2011 ; 44 : 337-425.
 
22) Kestenbaum B, Gillen DL, Sherrard DJ, et al. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int. 2002 ; 61 : 2157-64.
PubMed
23) Nakao K, Makino H, Morita S, et al. Beta-blocker prescription and outcomes in hemodialysis patients from the Japan Dialysis Outcomes and Practice Patterns Study. Nephron Clin Pract. 2009 ; 113 : c132-9.
PubMed
24) Shoji T, Tsubakihara Y, Fujii M, et al. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004 ; 66 : 1212-20.
PubMed
25) MacEwen C, Sutherland S, Daly J, et al. Relationship between hypotension and cerebral ischemia during hemodialysis. J Am Soc Nephrol. 2017 ; 28 : 2511-20.
PubMed
26) 日本透析医学会. 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌. 2012 ; 45 : 301-56.
 
27) Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients : a meta-analysis. Am J Kidney Dis. 2007 ; 49 : 674-81.
PubMed
28) Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011 ; 305 : 2184-92.
PubMed
29) Schneider AL, Williams EK, Brancati FL, et al. Diabetes and risk of fracture-related hospitalization. Diabetes Care. 2013 ; 36 : 1153-8.
PubMed
30) Inaba M, Okuno S, Kumeda Y, et al. Increased incidence of vertebral fracture in older female hemodialyzed patients with type 2 diabetes mellitus. Calcif Tissue Int. 2005 ; 76 : 256-60.
PubMed
31) Sasaki N, Tsunoda M, Ikee R, et al. Efficacy and safety of eldecalcitol, a new active vitamin D3 analog, in the bone metabolism of postmenopausal women receiving maintenance hemodialysis. J Bone Miner Metab. 2015 ; 33 : 213-20.
PubMed
32) Saito O, Saito T, Asakura S, et al. Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes. Int J Endocrinol Metab. 2012 ; 10 : 464-9.
 
33) 永作大輔, 高橋竜平. 骨粗鬆症を合併する外来透析患者に対するデノスマブ治療に関する前向き臨床研究-治療開始1年間の経過-. 透析会誌. 2017 ; 50 : 247-53.
 
34) Couchoud C, Bolignano D, Nistor I, et al. Dialysis modality choice in diabetic patients with end-stage kidney disease : a systematic review of the available evidence. Nephrol Dial Transplant. 2015 ; 30 : 310-20.
PubMed
35) Sanchez JE, Ortega T, Rodriguez C, et al. Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure. Nephrol Dial Transplant. 2010 ; 25 : 605-10.
PubMed
P.190 掲載の参考文献
1) 日本腎臓学会, 編. CKD診療ガイド 2012. 東京 : 東京医学社 ; 2012. p.73-5.
 
2) 日本透析医学会, 編. 血液透析患者の糖尿病治療ガイド 2012. 透析会誌. 2013 ; 46 : 334-9.
 
3) 日本糖尿病学会. メトホルミンの適正使用に関するRecommendation. http://www.fa.kyorin.co.jp/jds/uploads/recommendation_metformin.pdf
 
4) Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3) : an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017 ; 5 : 951-64.
PubMed
5) Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 ; 373 : 2117-28.
PubMed
6) Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of kidney disease in type 2 diabetes. N Engl J Med. 2016 ; 375 : 323-34.
PubMed
7) Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017 ; 377 : 644-57.
PubMed
8) Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 ; 375 : 311-22.
PubMed
9) Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. Engl J Med. 2016 ; 375 : 1834-44.
 
P.197 掲載の参考文献
1) Katayama S, Moriya T, Tanaka S, et al. Low transition rate from normoand low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals : the Japan Diabetes Complications Study (JDCS). Diabetologia. 2011 ; 54 : 1025-31.
 
2) Bruno G, Merletti F, Biggeri A, et al. Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes : the Casale Monferrato Study. Diabetologia. 2005 ; 48 : 427-34.
 
3) Araki S-i, Haneda M, Sugimoto T, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes. 2005 ; 54 : 2983-7.
 
4) Gade P, Vedel P, Parving H-H, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria : the Steno type 2 randomised study. Lancet. 1999 ; 353 : 617-22.
 
5) Gade P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 ; 348 : 383-93.
 
6) Gade P, Lund-Andersen H, Parving H-H, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008 ; 358 : 580-91.
 
7) Gade P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria : 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016 ; 59 : 2298-307.
 
8) Oellgaard J, Gade P, Rossing P, et al. Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. Kidney Int. 2017 ; 91 : 982-8.
 
9) Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 ; 359 : 1577-89.
PubMed
10) Fogelfeld L, Hart P, Miernik J, et al. Combined diabetes-renal multifactorial intervention in patients with advanced diabetic nephropathy : Proof-ofconcept. J Diabetes Complications. 2017 ; 31 : 624-30.
 
11) Shikata K, Haneda M, Koya D, et al. Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan) : rationale and study design. Diabetes Res Clin Pract. 2010 ; 87 : 228-32.
PubMed
P.206 掲載の参考文献
1) 医療スタッフの協働・連携によるチーム医療の推進について. 厚生労働省医政局長通知 (平成22年4月30日付医政発0430第1号).
 
2) チーム医療の推進について (チーム医療の推進に関する検討会 報告書). 平成22年3月19日. 厚生労働省.
 
3) 日本糖尿病学会. http://www.jds.or.jp/modules/important/index.php?page=article&storyid=92
 
4) Gade P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 ; 348 : 383-93.
 
5) Gade P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria : 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016 ; 59 : 2298-307.
 
6) Yamagata K, Makino H, Iseki K, et al ; Study Group for Frontier of Renal Outcome Modifications in Japan (FROM-J). Effect of behavior modification on outcome in early-to moderate-stage chronic kidney disease : a cluster-randomized trial. PLoS One. 2016 ; 11 : e0151422.
 
7) Shikata K, Haneda M, Koya D, et al ; DNETT-Japan Study Group. Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan) : Rationale and study design. Diabetes Res Clin Pract. 2010 ; 87 : 228-32.
 
P.217 掲載の参考文献
1) Shikata K, Makino H. Microinflammation in the pathogenesis of diabetic nephropathy. J Diabetes Investig. 2014 ; 18 : 142-9.
 
2) Wada T, Furuichi K, Sakai N, et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 2000 ; 58 : 1492-9.
PubMed
3) Nakamura A, Shikata K, Hiramatsu M, et al. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care. 2005 ; 28 : 2890-5.
PubMed
4) 名越智古, 吉村道博. ミネラルコルチコイド受容体拮抗薬. 血圧. 2016 ; 23 : 202-6.
Medical*Online
5) Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy : a randomized clinical trial. JAMA. 2015 ; 314 : 884-94.
PubMed
6) 片山茂裕. 糖尿病腎症の治療. 臨床高血圧. 2014 ; 20 : 90-8.
Medical*Online
7) de Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014 ; 25 : 1083-93.
PubMed
8) 山本伸也, 柳田素子. Bardoxolone methylに学ぶCKDの可能性. 医学のあゆみ. 2014 ; 249, 627-8.
 
9) Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney func tion in CKD with type 2 diabetes. N Engl J Med. 2011 ; 365 : 327-36.
 
10) de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013 ; 369 : 2492-503.
PubMed
11) Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 ; 373 : 2117-28.
PubMed
12) Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016 ; 375 : 323-34.
PubMed
13) Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011 ; 54 : 965-78.
 
14) Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 ; 375 : 311-22.
PubMed

書評

最近チェックした商品履歴

Loading...